Strategy and Value Creation | FUJIFILM, from | Top Management | Strategy and | Corporate Governance | Financial and | |||||||
Founding to Now | Commitment | Value Creation | Corporate Information | |||||||||
The Fujifilm Group's Vision and Ideals | Realization of | |||||||||||
a Sustainable Society |
In April 2021, we formulated the new medium-term management plan VISION2023 covering fiscal 2021 to fiscal 2023. This action plan guides us toward achieving the goals set forth in Sustainable Value Plan 2030 (SVP2030), a long-term plan targeting fiscal 2030.
We will accelerate the growth of the Fujifilm Group and contribute to the realization of a sustainable society by promoting the priority measures set forth in VISION2023, and by providing valuable products and services based on our leading-edge, proprietary technologies.
Targets Under SVP2030
Fiscal 2030
Revenue: JPY 3,500.0 billion or more
CO2 emissions*: Down 45% (vs. fiscal 2013)
SVP
2030
through
- Resolving global environmental and social issues with innovation
- Impacting society in a positive way through a wide range of business
- Adequately responding to the expectations of society through stakeholder engagement
Targets Under VISION2023
Fiscal 2023
Revenue: JPY 2,700.0 billion
Operating income: JPY 260.0 billion
CO2 emissions*: Down 38% (vs. fiscal 2013)
VISION
2019
Fiscal 2017: Formulation of SVP2030
VISION
2023
Achievements under VISION2019
Fiscal 2019
Revenue: JPY 2,315.1 billion
Operating income: JPY 186.6 billion
CO2 emissions*: Down 30% (vs. fiscal 2013)
- CO2 emission reductions are based on the entire product life cycle.
Targets are set in four priority areas and in the basis of our business activities via a two-pronged approach: considering society and the environment in our business processes and resolving social issues through our business activities.
Priority Areas | Business Segments Goals in the SDGs | |||||||||||||||||||
• Address climate change | Healthcare | |||||||||||||||||||
Environ- | • Promote recycling of resources | Materials | ||||||||||||||||||
ment | • Address energy issues | Business Innovation | ||||||||||||||||||
• Ensure product and chemical safety | Imaging | |||||||||||||||||||
•Reduce healthcare disparities and | ||||||||||||||||||||
Health | build a healthy society through the | |||||||||||||||||||
global provision of leading-edge | Healthcare | |||||||||||||||||||
products and services in all areas of | ||||||||||||||||||||
prevention, diagnosis and treatment | ||||||||||||||||||||
•Contribute to the creation of a | ||||||||||||||||||||
safe and secure society in the | ||||||||||||||||||||
age of advancing DX through the | ||||||||||||||||||||
development and provision of | ||||||||||||||||||||
Daily | leading-edge functional materials | Materials | ||||||||||||||||||
Contribute to enriching and making | ||||||||||||||||||||
Life | ||||||||||||||||||||
•people's lives peaceful through | Imaging | |||||||||||||||||||
the development and provision of | ||||||||||||||||||||
high-quality,high-performance | ||||||||||||||||||||
products and services in the field of | ||||||||||||||||||||
photography and videography | ||||||||||||||||||||
Work | •Contribute to social change where | |||||||||||||||||||
every person is motivated in the | ||||||||||||||||||||
Style | workplace through global provision of | Business Innovation | ||||||||||||||||||
products and solutions that increase | ||||||||||||||||||||
productivity and creativity | ||||||||||||||||||||
Basis of Business Activities | ||||||||||||||||||||
•Supply Chain | Strengthen CSR foundations across the entire supply chain | |||||||||||||||||||
•including factors of the environment, ethics and human rights | ||||||||||||||||||||
•Governance | Improve and maintain governance structures by further | |||||||||||||||||||
•disseminating an open, fair and clear corporate culture |
Process for Identifying Materiality
Step 1
Clarifying the Basic Policies
Have a long-term perspective to contribute to resolving social issues as a global company and show the future vision clearly
Step 2
Extracting Social Issues
Based on Business Strategy
List issues from external perspectives (e.g., various guidelines such as ISO 26000, GRI and the SDGs) and in terms of potential of issue resolution by all our divisions
Step 3
Evaluation of Materiality
Evaluate materiality via a two-pronged approach:
- Considering society and the environment in our business processes
- Resolving social issues through our business activities
Step 4
Planning and Review
Promote measures as companywide policy after coordinating goals for identified materiality with the relevant business divisions and finalizing materiality in the deliberations at the ESG Committee
For details of each step, please see the Sustainability Report 2021 Management Performance, pages 9-12.
23 FUJIFILM Holdings Corporation | INTEGRATED REPORT 2021 24 |
Strategy and Value Creation
Opportunities, Risks, Targets and Initiatives in Priority Areas
By assessing opportunities and risks and setting targets for initiatives in each of our priority areas, and by developing these initiatives in our business segments, we aim to resolve social issues through our business activities.
Priority | Opportunities | Risks | Main Business |
Areas | Segments | ||
FUJIFILM, from | Top Management | Strategy and | Corporate Governance | Financial and | ||||
Founding to Now | Commitment | Value Creation | Corporate Information | |||||
Major Initiatives and Targets for Priority Areas per Business
Target 1 Reduce CO2 emissions over product life cycles*1
Investment with Consideration of
Environmental Impact
Environ-
ment
- Growing needs for efficiently storing enormous volumes of data with less energy and at low cost in the era of big data
- Increasing demand for systems, products and technologies for weather monitoring and prediction in response to abnormal weather events, and for diagnosing deterioration of infrastructure such as buildings and water sources
● Supply chain disruptions and factory stoppages due |
to abnormal weather events caused by temperature |
increases (e.g., heavy rain, floods, drought, forest |
thinning) |
● Material shortages due to tree and forest withering |
(Paper: pulp, Film: cellulose) |
● Material shortages due to fossil fuel depletion |
● Increase in manufacturing costs due to carbon taxes |
on fossil fuel |
● Securing water necessary for film production to |
mitigate natural disasters, etc. |
Healthcare
Materials
Business
Innovation
Imaging
Goals in the SDGs
FY2019 (Actual) | FY2030 (Target) |
Target 2 Reduce CO2 emissions through products and services*2
- Incorporating contribution to decarbonization in investment decisions
- Targeting implementation of renewable energy at the new bio CDMO factories
Energy Strategy
- Switching to high-efficiency facilities across the Group
- Promoting social infrastructure development through environmental initiatives
Creating and Promoting Environmentally Conscious Products
● Increasing needs for solutions that support medicine | ● Major, unpredictable changes in healthcare | |
and improve work efficiency due to an aging | administration policies due to healthcare reforms | |
population and shortages of medical practitioners | ● Strengthened laws and regulations for medical | Healthcare |
● Increasing unmet medical needs, mainly for cancer, | equipment | |
rare diseases and gene therapies | ● Increasing difficulty of new drug discovery | |
● Expanding market for biopharmaceuticals, which |
16 | 90 | |
million tons | ||
million tons | ||
FY2019 (Actual) | FY2030 (Target) |
- Reducing society's power consumption through promoting use of large-capacity magnetic tape as an alternative to hard disk drives
- Reducing power load by introducing printing plate materials that do not need development processing
- Developing materials contributing to energy storage
are expected to deliver high efficacy with few | ● Heightened competition in the market for contract | Goals in the SDGs | |
Health | process development and manufacturing of | ||
side effects | |||
biopharmaceuticals due to technological innovations |
- Enhanced industrialization of regenerative medicine
- Rising awareness of healthy life expectancy and lifestyle-related ailments
● Stronger demand for display-related materials with | ● Tougher competition from alternative materials for | ||
growth in the OLED market | TAC film | ||
● Expansion in the semiconductor market from spread | ● Fierce competitive environment in the | ||
of 5G and autonomous driving | semiconductor materials market | ||
● Expansion in the industrial printing markets for | ● Weaker-than-expected demand in graphic arts film | ||
packaging and textiles, and growth in inkjet digital | and printing plates | Materials | |
printing in these markets | ● Higher raw materials prices | ||
Imaging | |||
● Growth in the number of images taken and printing | ● Escalation of competition in the mirrorless digital | ||
needs due to smartphone proliferation | camera market | ||
● Expansion of demand for instant photo systems in | |||
Daily | ● Enhancement of smartphone camera performance | Goals in the SDGs | |
emerging countries | (driving users away from cameras) | ||
Life | ● Single-lens reflex camera and smartphone users | ||
● Escalation of competition in the high-performance | |||
switching over to or purchasing mirrorless digital | industrial lens market due to competitors' | ||
cameras due to enhanced performance | |||
technological enhancements | |||
● Growth in demand for lenses as IoT advances and | |||
● Procurement risk due to tight supply-demand | |||
security becomes more important | balance in semiconductors |
- Increase in demand for high-performance lenses from shifts to 4K and 8K imaging
*1 Reducing CO2 in the entire product life cycle (Figures vs. fiscal 2013 levels)
*2 Target of CO2 emissions reduction in society, which is to be achieved by replacing the conventional products with our environmentally conscious products and services (Cumulative reduction since fiscal 2017)
Target Implementing medical AI-based products and services in all countries and regions
57 | 196 | ● Implementing products and services based on | |
medical AI technology in all countries and regions | |||
countries | countries | by fiscal 2030 to improve access to healthcare | |
FY2019 (Actual) | FY2030 (Target) |
Target 1 Contribute to creation of a safe and secure society in the age of advancing DX through the development and provision of leading-edge functional materials
Target 2 Contribute to enriching and making people's lives peaceful through the development and provision of high-quality,high-performance products and services in the field of photography and videography
Work Style
- Stronger demand for office equipment and related services in emerging markets such as China and Southeast Asia
- Increased demand for IT infrastructure development/ management services related to security, network and so forth, in response to the changes in work environments such as telecommuting
- Growing market for business solutions and services that utilize AI and the cloud for DX and improving productivity in office work
- Decreased demand for printing with establishment of telecommuting and advancements in business process digitization
- Decline in profitability due to tougher competition in office equipment markets
Business
Innovation
Goals in the SDGs
Target Provide solutions and services bringing business innovation to 50 million people around the world
50 | ● Providing 50 million workers with work styles helping |
them be more productive and creative through | |
solutions and services that bring innovation to their | |
million people | businesses |
FY2030 (Target) |
25 FUJIFILM Holdings Corporation | INTEGRATED REPORT 2021 26 |
Strategy and Value Creation
Targets for Achieving SVP2030 and Initiatives in Fiscal 2020
FUJIFILM, from | Top Management | Strategy and | Corporate Governance | Financial and | ||||
Founding to Now | Commitment | Value Creation | Corporate Information | |||||
Reflecting on the VISION2019 Medium-Term Management Plan, and on Fiscal 2020
Priority Area | Priority Issues | Major Targets for FY2030 | Major Activities in FY2020 | ||||
● Reduce the Fujifilm Group's | ● Raising our FY2030 targets for reducing CO2 | ||||||
1. Address climate change | CO2 emissions by 45% by | emissions | |||||
FY2030 (compared to the | (Targets on the left are revised targets) | ||||||
2. Promote recycling of | |||||||
FY2013 level) | ● Obtained SBTi certification with higher targets | ||||||
resources | |||||||
● Contribute to a reduction in the | ● Newly certified 30 products under the Fujifilm | ||||||
3. Address energy issues | |||||||
CO2 emissions generated in | Group Green Value Products certification system | ||||||
toward a decarbonized | |||||||
society by 90 million tons by | (total: 166 products) | ||||||
Environment | society | ||||||
FY2030 | ● Named on the CDP A List for Water Security, | ||||||
4. Ensure product and | ● Minimize adverse effect of | ||||||
earned the highest "Leadership" rank in the CDP | |||||||
chemical safety | chemical substances on human | Supplier Engagement Rating for three consecutive | |||||
health and the environment | years | ||||||
● First time selected for Health and Productivity | |||||||
1. Fulfill unmet medical needs | ● Develop new treatment | Stock Program | |||||
2. Improve accessibility to | solutions / Improve | ● Opened a cancer-focused medical screening | |||||
accessibility to new treatment | center in India | ||||||
medical services | |||||||
solutions | ● Released PCR test kits, manufactured APIs for | ||||||
3. Contribute to identifying | |||||||
● Expand and scale up AI and IoT | COVID-19 vaccine candidates and provided | ||||||
diseases at an early stage | |||||||
technologies to reduce burden | contract manufacturing for drug preparations | ||||||
4. Contribute to health | |||||||
Health | on medical professionals | ● Announced large-scale investments in Denmark | |||||
promotion and beauty | |||||||
5. Promote management of a | ● Promote management of | and U.S. biopharmaceutical manufacturing | |||||
health and productivity to | facilities | ||||||
healthy workplace | maintain employees' vitality | ● Launched SYNAPSE Radiotherapy, a radiotherapy |
Enhancing our business portfolio and building the foundation for the next leap forward
In the VISION2019 medium-term management plan, we positioned our businesses in the following three stages: improving profitability, accelerating further growth and investing to create a future. Taking measures according to the stage of growth, we worked to improve the profitability of each business and set priority issues such as accelerating growth in the healthcare field and establishing a new growth strategy and further improving profitability of the document solutions business.
In healthcare, with the medical systems business and the bio CDMO business as growth drivers, we have been proactively making investments for sustainable growth, including the acquisition of Hitachi, Ltd.'s diagnostic imaging business, the acquisition of a facility in Denmark for the bio CDMO business and large-scale capital investment. In the document solutions business, we achieved an operating
margin of more than 10% in fiscal 2019, one year ahead of the initial plan, by improving profitability through promotion of operational reforms and shortening development lead times. In addition, by making Fuji Xerox a wholly owned subsidiary of the Company, we have established a foundation that will lead to faster decision-making and further synergy creation within the Fujifilm Group.
VISION2019 | FY2019 | FY2020 | ||
(Actual) | (Actual) | |||
Revenue | 2,600.0 | 2,315.1 | 2,192.5 | |
100% | 100% | 100% | ||
Operating | 230.0 | 186.6 | 165.5 | |
income | 8.8% | 8.1% | 7.5% | |
Net income | 150.0 | 125.0 | 181.2 | |
attributable | Record | |||
to FUJIFILM | 5.8% | 5.4% | high | 8.3% |
Holdings | ||||
ROE* | 7.3% | 6.3% | 8.7% |
* Return on equity
planning support software that utilizes AI in Japan | |||
1. Contribute to creating a | ● Aim at 100% preservation of | ● Developed technology for magnetic tape storage | |
media with high recording capacity of 580TB, | |||
safe and secure society | records archived on tapes. | ||
which is 50x the conventional capacity | |||
2. Contribute to enriching | ● Offering opportunities to enjoy | ||
● Enhanced the AI functionality of "Hibimikke (Crack | |||
humanity and relationships | photos that give forms to | ||
Daily Life | Finder)" a social infrastructure image diagnostic | ||
between people | memories | ||
service | |||
Addressing Priority Issues and Performance Trends
Priority issues | Measures FY2017 | FY2018 | FY2019 | FY2020 |
Acquisition of Biogen | Bio CDMO business | |||
Accelerating growth in | Acquisition of Wako Pure | Acquisition of Irvine | (Denmark) Manufacturing | Decision to make large-scale |
Decision to acquire Hitachi, | ||||
the healthcare field | Chemical Industries, Ltd. | Scientific | capital investment | |
Ltd.'s diagnostic imaging | Transfer of J-TEC shares | |||
business* | ||||
Establishing a new | Converted Fuji Xerox to a | Established FUJIFILM | ||
growth strategy and | Announced structural | wholly owned subsidiary | ||
RIPCORD, a service company | ||||
further improving | Decided to terminate the | |||
reforms at Fuji Xerox | to drive DX alongside | |||
profitability of the | technology agreement with | U.S.-based RIPCORD | ||
document solutions business | U.S.-based Xerox Corporation | |||
1. Create environments | ● Support work-style reform for | |
that lead to a motivated | ||
customers | ||
workplace | ||
● Improve the rate of women in | ||
2. Develop and utilize diverse | ||
Work Style | managerial positions | |
human resources |
Strengthen CSR foundations | ||
● Supply Chain | across the entire supply | ● Promote sustainable |
chain including factors of | ||
procurement | ||
the environment, ethics and | ||
human rights
● Received the Nikkei Superior Products and |
Services Award and the Nikkei Business Daily |
Award for the CocoDesk personal workspace, |
supporting telecommuting for businesspersons |
● Launched provision of our IT Expert Service, an |
outsourcing service helping SMEs to leverage IT |
● Improved the rate of women in managerial positions |
(14.5% in FY2019 to 15.4% in FY2020) |
● Re-informed our suppliers across the world about |
the Request to Suppliers and collected receipts |
from 213 suppliers |
* Acquisition completed on March 31, 2021 | |||||
Healthcare Field: Performance Trends | Document Solutions Business: Performance Trends | ||||
Revenue Operating income | Operating margin | Revenue Operating income | Operating margin | ||
(Billions of yen) | 567.8 | (Billions of yen) | ||||||||||
600 | 504.1 | 12.0% | 1,200 | 1,047.8 | 1,005.6 | 14.0% | ||||||
484.3 | 958.3 | |||||||||||
443.0 | ||||||||||||
854.7 | ||||||||||||
9.8% | 11.0% | |||||||||||
9.6% | ||||||||||||
6.8% | 8.6% | |||||||||||
300 | 6.6% | 6.0% | 600 | 7.0% | ||||||||
4.5% | 33.3 | 33.1 | 55.8 | 0.8% | 96.4 | 105.0 | 73.3 | |||||
19.7 | 8.4 | |||||||||||
0 | FY2017 | FY2018 | FY2019 | FY2020 | 0 | FY2017 | FY2018 | FY2019 | FY2020 |
Improve and maintain | ● Improve compliance awareness | |
● Governance | governance structures by | |
across the entire global Group | ||
further disseminating an open, |
fair and clear corporate culture | and reinforce risk management |
● Establishment of the Fujifilm Group AI Policy |
● Revision of Corporate Governance Guidelines |
● Establishment of the Fujifilm Group Global |
Healthcare Code of Conduct and providing |
education to employees engaged in related |
businesses |
● Surveying all Group employees on understanding |
of Company policies and awareness of compliance |
A business portfolio with steady profits, even amid the COVID-19 pandemic
In fiscal 2020, both sales and profits decreased year-over- year due to the impact of the spread of COVID-19, but the medical systems business, bio CDMO business and regenerative medicine business performed particularly well in contributing to pandemic control. Sales also increased in the highly functional materials field, which captured demand for working and learning at home. This was a year
in which we built a resilient business portfolio and generated solid profits even amid the COVID-19 pandemic. In addition, net income attributable to FUJIFILM Holdings reached a record high, thanks to gains on the sale and valuation of investment securities, which gained significant value from strategic investments in venture companies, mainly in the healthcare segment. Also contributing were improvements in losses attributable to noncontrolling interests as a result of converting Fuji Xerox into a wholly owned subsidiary.
27 FUJIFILM Holdings Corporation | INTEGRATED REPORT 2021 28 |
Strategy and Value Creation
Medium-Term Management Plan VISION2023
In April 2021, we announced our medium-term management plan VISION2023, effective through fiscal 2023. Through four priority measures, we will accelerate growth in healthcare and highly functional materials and build a more resilient business platform to facilitate sustainable growth.
Accelerate business growth in healthcare and advanced materials and build a more resilient business platform to facilitate sustainable growth
- Continue active growth investments
- Concentrate management resources on "New/Future Potential" and "Growth Driver" businesses
- Accelerate and strengthen the cash generation and investment cycle
FUJIFILM, from | Top Management | Strategy and | Corporate Governance | Financial and | ||||
Founding to Now | Commitment | Value Creation | Corporate Information | |||||
Performance Targets | (Billions of yen) | ||||||
FY2021 | FY2021 | FY2023 | |||||
FY2020 (Actual) | Latest Earnings | ||||||
VISION2023 | VISION2023 | ||||||
Forecast*6 | |||||||
Revenue | 2,192.5 | 2,440.0 | 2,500.0 | 2,700.0 | |||
100% | 100% | 100% | 100% | ||||
Operating income | 189.5 | 215.0 | 235.0 | 270.0 | |||
(Excluding one-time expenses) | 8.6% | 8.8% | 9.4% | 10.0% | |||
One-time expenses | 24.0 | 35.0 | 35.0 | 10.0 | |||
165.5 | 180.0 | 200.0 | 260.0 | ||||
Operating income | Record | ||||||
7.5% | 7.4% | 8.0% | high | 9.6% | |||
1 Reinforce business portfolio management
Implement appropriate strategies according to business phase
Optimal allocation of group-wide management resources
3 Enter into new markets for further growth
Continue to invest in fields and markets where our technological strengths*4 can be leveraged
2 Strengthen cash flow management
Thorough business approach that emphasizes capital efficiency
Improve ROE*1, ROIC*2 and CCC*3
4 Create stronger integrated business synergies through M&A
FUJIFILM Healthcare*5
→Combine AI technology with our extensive product lineup to create new value
Income before | 235.9 | 185.0 | 220.0 | 265.0 | |
Record | |||||
income taxes | 10.8% | 7.6% | 8.8% | high | 9.8% |
Net income attributable to | 181.2 | 130.0 | 160.0 | 200.0 | |
Record | |||||
FUJIFILM Holdings | 8.3% | 5.3% | 6.4% | high | 7.4% |
Earnings per share for net income | ¥453.28 | ¥325.18 | ¥400.18 | ¥500.27 | |
attributable to FUJIFILM Holdings | |||||
ROE | 8.7% | 6.2% | 7.1% | 8.4% | |
ROIC | 4.3% | 4.6% | 4.9% | 6.1% | |
CCC | 123 days | 124 days | 124 days | 103 days |
FUJIFILM Business Innovation
-
• Accelerate global business deployment
• Strengthen solution and service businesses
(Note 1) Fiscal 2020 exchange rates (actual): USD = JPY 106, EUR = JPY 124, silver price (per kg) = JPY 84,000 VISION2023 exchange rate assumptions: USD = JPY 104, EUR = JPY 124, silver price (per kg) = JPY 84,000 Latest exchange rate forecast for fiscal 2021: USD = JPY 109, EUR = JPY 132, silver price (per kg) = JPY 95,000
(Note 2) Operating income fluctuation per change in one foreign exchange unit: USD = JPY 0.3 billion, EUR = JPY 0.8 billion
VISION2023:
Four priority measures
VISION2023 is based on the principles of accelerating growth in healthcare and highly functional materials and building a more resilient business platform to facilitate sustainable growth. Here, we will promote four priority measures to achieve these goals.
Reinforce business portfolio management
With our business segments reorganized into four areas- Healthcare, Materials, Business Innovation and Imaging- we will execute strategies befitting the phase of each business within these segments, with each business classified into one of four stages-New/Future Potential, Growth Driver, Earnings Base and Non-Core.
Strengthen cash flow management
In addition to growth in revenue and operating income and achieving ROE targets, we will adopt ROIC and CCC as new indicators and strengthen our ability to generate cash, through rigorous business management mindful of capital efficiency. In particular, we will focus on ROIC, an indicator of management efficiency in terms of effectively utilizing
invested capital, with a group-wide target of 6.1% in fiscal 2023. In addition, through the efficient use of assets and business portfolio management, we will generate a cumulative total of JPY 1 trillion in operating cash flow over three years, which we will prioritize use in growth investment.
Enter into new markets for further growth
We will invest in areas where we can leverage the Fujifilm Group's technological strengths, such as AI technology, biotechnology and photo regulation materials technology as we work to enter new markets.
Create stronger integrated business synergies through M&A
Fujifilm will create synergistic benefits with FUJIFILM Healthcare, which has taken over Hitachi, Ltd.'s diagnostic imaging business. Also, FUJIFILM Business Innovation will generate integration benefits in accelerating global operational presence and reinforcing the Solutions & Services Business.
*1 Return on equity
*2 Return on invested capital
*3 Cash conversion cycle. Number of days from when payment is made to purchase raw materials to when payment is collected for products or services
*4 AI/IT technologies, biotechnology, optical control material technology, etc. *5 Successor company for diagnostic imaging business of Hitachi, Ltd. acquired
on March 31, 2021
Performance Targets in the
VISION2023: Record profits
We are targeting revenue of JPY 2.7 trillion in fiscal 2023, with operating income to reach a record high in fiscal 2022 and further grow in fiscal 2023. Our goal for net income attributable to FUJIFILM Holdings is to reach a record high of JPY 200 billion in fiscal 2023. The plan does not incorporate one-time gains such as the gain on the sale and valuation of investment securities recorded in fiscal 2020, but it does include expected temporary profit declines in fiscal 2021. In addition, we will achieve ROE of 8.4% in fiscal 2023.
*6 As of the Q1 fiscal 2021 financial results announcement *7 After segment eliminations
*8 Fiscal 2020 figures are forecasts as of the time when VISION2023 was announced
*9 Revenue in the fiscal 2020 earnings forecast reference data is based on the reclassification of revenue from "Production Services" under Business Innovation (Document Solutions) to the Materials area in the forecast announced on February 9, 2020 (reference data)
Performance Targets by Segment | (Billions of yen) | |||
FY2021 | FY2021 | FY2023 | ||
Revenue*7 | FY2020*8 | Latest Earnings | ||
VISION2023 | Forecast*6 | VISION2023 | ||
Healthcare | 550.0 | 750.0 | 770.0 | 860.0 |
Materials*9 | 570.0 | 600.0 | 620.0 | 720.0 |
Business | 780.0 | 800.0 | 800.0 | 820.0 |
Innovation*9 | ||||
Imaging | 280.0 | 290.0 | 310.0 | 300.0 |
Total | 2,180.0 | 2,440.0 | 2,500.0 | 2,700.0 |
Operating income | FY2021 | FY2021 | FY2023 | |
[Operating | FY2020*7 | Latest Earnings | ||
margin] | VISION2023 | Forecast*6 | VISION2023 | |
Healthcare | 56.0 | 70.0 | 78.0 | 103.0 |
[10.2%] | [9.3%] | [10.1%] | [12.0%] | |
Materials | 52.0 | 56.0 | 62.0 | 95.0 |
[9.1%] | [9.3%] | [10.0%] | [13.2%] | |
Business | 71.0 | 75.0 | 75.0 | 82.0 |
Innovation | [9.1%] | [9.4%] | [9.4%] | [10.0%] |
Imaging | 11.0 | 16.0 | 22.0 | 25.0 |
[3.9%] | [5.5%] | [7.1%] | [8.3%] | |
Corporate expenses / | -30.0 | -37.0 | -37.0 | -45.0 |
consolidated | ||||
adjustment | ||||
Total | 160.0 | 180.0 | 200.0 | 260.0 |
[7.3%] | [7.4%] | [8.0%] | [9.6%] | |
29 FUJIFILM Holdings Corporation | INTEGRATED REPORT 2021 30 |
Strategy and Value Creation
Medium-Term Management Plan VISION2023
Message from CFO
Strengthening our business portfolio management and building a more resilient business foundation facilitating sustainable growth
Masayuki Higuchi
Director and Corporate Vice President
CFO and General Manager of
Corporate Planning Division
FUJIFILM Holdings Corporation
Reinforcing Business Portfolio Management-Strategic execution fitting business phases
FUJIFILM, from | Top Management | Strategy and | Corporate Governance | Financial and | ||||
Founding to Now | Commitment | Value Creation | Corporate Information | |||||
Planting seeds from a long-term perspective | Driving growth and profit in the medium term | |||||||||||
High | ||||||||||||
New/Future Potential | Growth Driver | |||||||||||
Medical Systems: | Medical Systems: | |||||||||||
AI/IT systems, endoscopes (rigid endoscopes, | Endoscopes (flexible endoscopes, treatment tools) | |||||||||||
surgical tools) | IVD (equipment, reagents) | |||||||||||
potential) | ||||||||||||
Bio CDMO: Gene therapeutics CDMO | Diagnostic ultrasound systems (POC, stationary) | |||||||||||
Life Sciences: Drug discovery support | X-ray equipment (CT, MRI, DR, etc.) | |||||||||||
Bio CDMO: | ||||||||||||
(iPS cells, cell culture media, reagents) | ||||||||||||
Electronic Materials, Display Materials and Other | Antibody drug CDMO | |||||||||||
(growth | Electronic Materials: | |||||||||||
Advanced Materials: New materials | etc. | |||||||||||
Graphic Communication: | Semiconductor materials | |||||||||||
Digital printing, inkjet | ||||||||||||
Business Solutions | etc. | |||||||||||
attractiveness | Non-Core | Earnings Base (cash cows) | ||||||||||
Market | Judged based on compatibility with strategy, growth | Office Solutions | ||||||||||
potential and profitability | Consumer Imaging | |||||||||||
Professional Imaging | ||||||||||||
Graphic Communication: | ||||||||||||
Analog printing | etc. |
Along with the formulation of our medium-term management plan VISION2023, we have reorganized our businesses into four segments: Healthcare, Materials, Business Innovation and Imaging. Starting in fiscal 2021, we are disclosing financial information such as revenue and
respective growth phases. In order to classify the businesses, we examined each business from various perspectives, including its positioning, potential and stage. Our basis for this examination is the approach of concentrating investment in areas where we can leverage
Low | Our profitability | High | |||
The arrows ( | ) indicate the flow of management resources, including cash. |
operating income for Healthcare as an independent segment to illustrate progress in this management plan.
In addition, each of our businesses will be categorized as one of New/Future Potential, Growth Driver, Earnings Base and Non-Core. For each of these, we will implement appropriate strategies and reallocate management resources across the Group in accordance with their
the Company's strengths and where we can generate higher returns over the medium to long term. We will concentrate investing our management resources into New/Future Potential and Priority businesses for growth, as these will drive our future generations. Meanwhile, we will pursue management efficiency and control investments in Earnings Base businesses, maximizing cash flow.
Specifically, over the three years of the VISION2023 plan, we will invest a total of more than 1.2 trillion yen in R&D, capital expenditures and other growth investments, of which 1 trillion yen will be concentrated in New/Future Potential and Priority businesses. By newly disclosing the revenue results of the medical systems business, bio CDMO business and electronic materials business, each are either New/Future Potential or Growth Driver, we will visualize the progress of growth in each of these businesses.
Revenue and Operating Income Composition
FY2020*1 | ||
13% | 25% | 6% |
30% | ||
Revenue | Operating | |
Income | ||
Composition | ||
Composition*2 |
Reorganizing into Four Business Segments
Medical Systems | Life Sciences | ||||||||||
Healthcare | Bio CDMO | • Life sciences (drug discovery support: iPS cells, cell culture media, reagents) | |||||||||
• Pharmaceuticals | |||||||||||
• Consumer healthcare (cosmetics, supplements) | |||||||||||
Other Advanced Materials | Graphic Communication | ||||||||||
Advanced Materials | |||||||||||
Materials | • Industrial products | • Graphic communication | |||||||||
Electronic Materials | |||||||||||
• Fine chemicals | • Inkjet | ||||||||||
Display Materials | • Recording media | ||||||||||
In the Earnings Base businesses, we will focus on profitability and efficiency to maximize cash generation and generate resources for investment in growth. Businesses that we have positioned as Non-Core in terms of strategic fit, growth potential and/or profitability will be examined with a view to either transforming them into Earnings Base businesses through thorough reform, or potentially disposing of them through sale or withdrawal.
Through these measures, we aim to grow Healthcare to become the Group's largest segment, with revenue accounting for 32% across the Group in fiscal 2023 (vs. 25% in fiscal 2020) and operating income of 34% in fiscal 2023 (vs. 30% in fiscal 2020).
36% | 26% | 37% | 27% |
Healthcare | Healthcare grows |
Materials | into largest segment |
Business Innovation | in both revenue and |
Imaging | operating income. |
FY2023 | ||
11% | 32% | 8% |
34% |
Business | Office Solutions | |
Innovation | Business Solutions | |
Imaging | Consumer Imaging | |
Professional Imaging | ||
As of fiscal 2021, results are disclosed for four segments (healthcare, materials, business innovation and imaging) and
11 subsegments ( )*
- Revenue and operating income are disclosed for the four segments, and revenue is disclosed for the 11 subsegments.
Revenue | Operating | |
Income | ||
Composition | ||
Composition*2 | ||
27% | ||
30% | 27% | 31% |
*1 Figures for fiscal 2020 are forecasts as of the time when the medium-term management plan was announced.
*2 Operating income composition■ ■ ■ data■ is売group上高-wide and before consolidation adjustments.
31 FUJIFILM Holdings Corporation
INTEGRATED REPORT 2021 32
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Fujifilm Holdings Corporation published this content on 29 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 November 2021 14:00:08 UTC.